BioCentury
ARTICLE | Clinical News

TAK-361S: Development discontinued

February 23, 2015 8:00 AM UTC

Takeda discontinued development of TAK-361S following a portfolio prioritization. The vaccine was in Phase II testing. Takeda said it will focus on developing vaccines to prevent norovirus infection, ...